Novartis AG AG on Wednesday released positive topline results from its pivotal Phase 3 RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU). The Disease The primary endpoint was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results